Monte Rosa Therapeutics (GLUE) Total Liabilities: 2023-2025
Historic Total Liabilities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $214.0 million.
- Monte Rosa Therapeutics' Total Liabilities rose 95.22% to $214.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.0 million, marking a year-over-year increase of 95.22%. This contributed to the annual value of $215.8 million for FY2024, which is 73.32% up from last year.
- Latest data reveals that Monte Rosa Therapeutics reported Total Liabilities of $214.0 million as of Q3 2025, which was up 133.87% from $91.5 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Total Liabilities registered a high of $215.8 million during Q4 2024, and its lowest value of $65.0 million during Q2 2023.
- For the 3-year period, Monte Rosa Therapeutics' Total Liabilities averaged around $118.6 million, with its median value being $114.2 million (2024).
- Within the past 5 years, the most significant YoY rise in Monte Rosa Therapeutics' Total Liabilities was 95.22% (2025), while the steepest drop was 23.39% (2025).
- Monte Rosa Therapeutics' Total Liabilities (Quarterly) stood at $124.5 million in 2023, then spiked by 73.32% to $215.8 million in 2024, then spiked by 95.22% to $214.0 million in 2025.
- Its Total Liabilities was $214.0 million in Q3 2025, compared to $91.5 million in Q2 2025 and $118.0 million in Q1 2025.